IntelliNews Questions Whether Africa's Cannabis Licensing Pays Off

The core claim: licences are running ahead of proof

IntelliNews's Oct. 10 analysis, headlined "Pipedream?", argues that African licensing activity has outrun evidence of commercial returns.

Africa's cannabis licensing push has outpaced evidence of commercial returns, IntelliNews reported Oct. 10. CannIntel worked from the report's headline and framing and hasn't independently verified its underlying figures.

Who licensed first, and what it bought them

Several African governments moved early, and early movers now face the sharpest test.

Lesotho licensed medical cannabis cultivation in 2017. Zimbabwe followed in 2018 with rules for medical and scientific production. In 2018, South Africa's Constitutional Court also decriminalized private use. Morocco passed Law 13-21 in 2021 for medical and industrial use.

Years on, one question remains. Did any of it turn into durable earnings?

The export problem sits outside Africa

Most business plans assume export revenue, and exports depend on approvals issued in Brussels, Berlin and Ottawa, not Maseru or Harare.

A European buyer typically needs EU-GMP-grade product and an import permit from a regulator such as Germany's BfArM. Canada's Health Canada applies its own import rules. Under the UN drug treaties, the INCB tracks national medical cannabis systems.

Home licences clear none of them.

The operator lens: capital before customers

Licensed growers often have to fund compliance-grade facilities before they can sign a foreign offtake.

That sequencing is the squeeze. Cultivation sites, testing and quality systems cost money up front. Buyers in regulated markets can walk away over a single failed audit or a documentation gap. Domestic demand is thin in most African markets, so a local sales fallback is weak.

Capital first. Customers later.

The investor lens: a pipeline is not a P&L

Investors should separate licences granted from product shipped and paid for.

Licence counts are easy to publish and flatter any policy tracker. Audited export volumes, realized prices and receivables are harder to find. That's the metric gap IntelliNews's headline points to, and it's a fair one to press.

What the evidence gap means for policy

Regulators who keep issuing licences without publishing performance data invite oversupply of permits and undersupply of buyers.

For a fuller look at how individual regimes compare, see the CannIntel topic hub on Africa cannabis licensing. Governments that publish export and tax data would let investors price the sector honestly, and would put pressure on weaker applicants.

What to watch

The next signal is verifiable export data from licensed African producers.

Watch for EU-GMP certifications granted to African sites, import approvals cleared by BfArM-type regulators, and any government that publishes licence-to-revenue figures. Until those appear, the "pipedream" question stays open.